Application of SCR priming VLP boosting as a novel vaccination strategy against HIV-1

Current HIV Research

Volumn 9, Issue 3, 2011, Pages 140-147

  Sadat, Seyed Mehdi ^a   Zabihollahi, Rezvan ^b   Aghasadeghi, Mohammad Reza ^b   Vahabpour, Rouhollah ^b   Siadat, Seyed Davar ^b   Memarnejadian, Arash ^b   Azadmanesh, Kayhan ^c   Parivar, Kazem ^a  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b Hepatitis and AIDS Dept   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

BALB c immunization; HIV; Montanide ISA720; Single cycle replicable; Vaccine; VLP

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 4; MONTANIDE ISA 720; SINGLE CYCLE REPLICABLE HUMAN IMMUNODEFICIENCY VIRUS 1 VIRION VACCINE; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; SINGLE CYCLE REPLICABLE HUMAN IMMUNODEFICIENCY VIRUS 1 VIRION; SPLEEN CELL; TECHNIQUE; TH1 CELL; VACCINATION; VIRION; VIRUS LIKE AGENT; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; CELLS, CULTURED; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; SPLEEN; VACCINATION; VACCINES, VIROSOME;

EID: 79959302378     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016211795945223     Document Type: Article

References (34)

1. Letvin NL, Barouch DH, and Montefiori DC. Prospects for vaccine protection against HIV-1 infection and AIDS. Annu Rev Immunol 2002; 20: 73-99.
2. Mcelrath MJ, Haynes BF. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 2010; 33(4): 542-54.
3. Borrow P, Lewicki H, Hahn BH, et al. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68: 6103-10.
4. Parren PW, Gauduin MC, Koup RA, et al. Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design. Immunol Lett 1997; 57: 105-12.
5. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998; 280: 1884-8.
6. Pantophlet R, Burton DR. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 2006; 24: 739-69.
7. Schonning K, Bolmstedt A, Novotny J, et al. Induction of antibodies against epitopes inaccessible on the HIV type 1 envelope oligomer by immunization with recombinant monomeric glycoprotein 120. AIDS Res Hum Retroviruses 1998; 14: 1451-6.
8. McBurney SP, Young KR, Nwaigwe CI, et al. Lentivirus-like particles without reverse transcriptase elicit efficient immune responses. Curr HIV Res 2006; 4: 475-84.
9. McBurney SP, Young KR, Ross TM. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. Virology 2007; 358: 334-46.
10. Girard MP, Osmanov SK, Kieny MP. A review of vaccine research and development: The human immunodeficiency virus (HIV), Vaccine 2006; 24(19): 4062-81.
11. Schneider J, Gilbert SC, Hannan CM, et al. Induction of CD8+ T cells using heterologous prime-boost immunization strategies. Immunol Rev 1999; 170: 29-38.
12. Ramshaw IA, Ramsay AJ. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 2000; 21(4): 163-5.
13. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292(5514): 69-74.
14. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiencyvirus immunity. Nature 2002; 415(6869): 331-5.
15. Rezaei A, Zabihollahi R, Salehi M, et al. Designing a non-virulent HIV-1 strain: potential implications for vaccine and experimental research. J Res Med Sci 2007; 12: 227-34.
16. Zabihollahi R, Sadat SM, Vahabpour R, et al. Development of single-cycle replicable human immunodeficiency virus 1 mutants. Acta Virologca 2011; 55: 15-22.
17. Sadat SM, Zabihollahi R, Vahabpour R, et al. Designing and biological evaluation of single-cycle replicable HIV-1 system as a potential vaccine strategy. Clin Microbiol Infect 2010; 16(2); S334. Vienna, Austria.
18. Biel SS, Gelderblom HR. Diagnostic electron microscopy is still a timely and rewarding method. J Clin Virol 1999; 13: 105-19.
19. Roohvand F, Aghasadeghi MR, Sadat SM, et al. HCV core protein immunization with Montanide/CpG elicits strong Th1/Th2 and long-lived CTL responses. BBRC 2007; 354: 641-649.
20. Mahdavi M, Ebtekar M, Azadmanesh K, et al. HIV-1 Gag p24-Nef fusion peptide induces cellular and humoral immune response in a mouse model. Acta Virol 2010; 54(2): 131-136.
21. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature 2008; 455(7213): 613-9.
22. Egan MA. Current prospects for the development of a therapeutic vaccine for the treatment of HIV type 1 infection. AIDS Res Hum Retrovir 2004; 20 (8): 794-806.
23. Sauter SL, Rahman A, Muralidhar G. Non-replicating viral vectorbased AIDS vaccines: interplay between viral vectors and the immune system. Curr HIV Res 2005; 3 (2): 157-181.
24. Marjorie RG. Replicating and Non-replicating Viral Vectors for Vaccine Development. Curr Opin Biotechnol 2007; 18(6): 546-56.
25. Koff WC, Johnson PR, Watkins DI, et al. HIV vaccine design: insights from live attenuated SIV vaccines. Nature Immunol 2006; 7: 19-23.
26. Pincha M, Sundarasetty B, Stripecke R. Lentiviral vectors for immunization: an inflammatory field. Expert Rev Vaccine 2010; 9(3): 309-21.
27. Miyoshi H, Blomer U, Takahashi M, et al. Development of a selfinactivating lentivirus vector. J Virol 1998; 72: 8150-7.
28. Lemiale F, Asefa B, Ye D, et al. An HIV-based lentiviral vector as HIV vaccine candidate: Immunogenic characterization. Vaccine 2010; 28(8): 1952-61.
29. Sachdeva S, Mohmmed A, Dasaradhi PV, et al. Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants, Vaccine 2006; 15: 2007-16.
30. Pan W, Huang D, Zhang Q, et al. Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro, J. Immunol 2004; 172: 6167-74.
31. Spearman P, Kalams S, Elizaga M, et al. Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. Vaccine 2009; 27: 243-9.
32. Ruedl C, Storni T, Lechner F, et al. Cross-presentation of virus-like particles by skin-derived CD8- dendritic cells: a dispensable role for TAP. Eur J Immunol 2002; 32(3): 818-25.
33. He Y, Falo Jr LD. Lentivirus as a potent and mechanistically distinct vector for genetic immunization. Curr Opin Mol Ther 2007; 9: 439-46.
34. Radcliffe JN, Roddick JS, Friedmann PS, et al. Prime-boost with alternating DNA vaccines designed to engage different antigen presentation pathways generates high frequencies of peptidespecific CD8+ T cells, J Immunol 2006; 177: 6626-33.